biomarker-trends-header.png

In Cancer Treatment, New DNA Tools - NYTimes.com

Foundation Medicine

Translational research: Crossing the valley of death : Nature News

Have we built any decent bridges over the last 5 years?

Who will fund the next generation of diagnostic tests?

More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges.

Diagnostic Errors Are the Most Common Type of Medical Mistake

Further motivation to drive the advancement of molecular diagnostics ever more vigorously.

Mathematical models out-perform doctors in predicting cancer patients responses to treatment

Mathematical models out-perform doctors in predicting cancer patients responses to treatment.

Post Mortem for a Diagnostics Company by a Founding Investor

On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC.

Genetic Analysis is Already a Commodity Product

Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court's decision on the patentability of BRCA1/BRCA2.

   

December

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report